We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: antibody-drug conjugates
MedXY News
EnglishTag

antibody-drug conjugates

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy
newsrecurrenceHER2

Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy

By MedXY|Aug 18, 2026

HER2 expression in recurrent cervical cancer varies notably by histology and recurrence site, underscoring the importance of reassessment to guide HER2-targeted treatments effectively.

Real-World Antibody-Drug Conjugate Outcomes in Gynecologic Cancers Appear Consistent Across Demographic Subgroups
newshealth disparitiesgynecologic cancers
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Real-World Antibody-Drug Conjugate Outcomes in Gynecologic Cancers Appear Consistent Across Demographic Subgroups

By MedXY|Aug 18, 2026

In a single-center real-world cohort, survival with mirvetuximab soravtansine, trastuzumab deruxtecan, and tisotumab vedotin broadly mirrored pivotal trials, with no independent survival differences by age, race, or ethnicity after adjustme

Targeting the Sugar Coat: Oncofetal Chondroitin Sulfate Emerges as a Precision ADC Target in AML
Hematology-Oncologyacute myeloid leukemiaantibody-drug conjugates

Targeting the Sugar Coat: Oncofetal Chondroitin Sulfate Emerges as a Precision ADC Target in AML

By MedXY|Mar 28, 2026

Researchers have identified oncofetal chondroitin sulfate (ofCS) as a novel target for antibody-drug conjugates in AML. Unlike traditional targets, ofCS is absent in healthy tissues, potentially reducing hematotoxicity and expanding treatme

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease
newsantibody-drug conjugatesimmunotherapy

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

By MedXY|Mar 4, 2026

The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for pati

Targeted HEV Modulation: A Novel Antibody-Drug Conjugate Strategy to Overcome Cardiac Allograft Rejection
Allergy & Immunologyantibody-drug conjugatesCardiac Transplantation

Targeted HEV Modulation: A Novel Antibody-Drug Conjugate Strategy to Overcome Cardiac Allograft Rejection

By MedXY|Mar 2, 2026

Researchers have developed a first-in-class antibody-drug conjugate targeting High Endothelial Venules via the CHST4 enzyme. This therapy promotes regulatory T cell induction and long-term heart transplant survival in murine models using si

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC
newsantibody-drug conjugatespembrolizumab

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC

By MedXY|Jan 25, 2026

The phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrates that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival and duration of response compared to standard chemotherapy plus pembrolizumab in patients wi

Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results
newsantibody-drug conjugatesDatopotamab Deruxtecan

Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results

By MedXY|Jan 9, 2026

The final TROPION-Breast01 analysis confirms datopotamab deruxtecan’s superior progression-free survival over chemotherapy in HR+/HER2- breast cancer. While overall survival did not reach significance, likely due to subsequent ADC cro

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer
newsantibody-drug conjugatesbreast cancer

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

By MedXY|Jan 9, 2026

Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-fre

Trastuzumab Deruxtecan in HER2-Overexpressing NSCLC: Efficacy, Safety, and the Challenges of Combination Therapy in DESTINY-Lung03
Clinical Updatesantibody-drug conjugatesNSCLC

Trastuzumab Deruxtecan in HER2-Overexpressing NSCLC: Efficacy, Safety, and the Challenges of Combination Therapy in DESTINY-Lung03

By MedXY|Jan 8, 2026

This review analyzes the Phase 1b DESTINY-Lung03 trial results, highlighting the robust efficacy of trastuzumab deruxtecan monotherapy in HER2-overexpressing NSCLC and the prohibitive toxicity encountered when combined with durvalumab and p

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know
Cardiologyantibody-drug conjugatesCardio-Oncology

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know

By MedXY|Nov 19, 2025

A 2025 meta-analysis of 9,538 patients found trastuzumab emtansine (T‑DM1) carries the lowest incidence of LVEF decline (0.94%), while trastuzumab deruxtecan (T‑DXd) and trastuzumab-based combinations show similar, modest rates (≈4–5%). Tri

Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial
Clinical Updatesantibody-drug conjugatespatritumab deruxtecan

Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial

By MedXY|Oct 6, 2025

The ICARUS-BREAST01 phase 2 trial demonstrated patritumab deruxtecan’s efficacy and manageable safety in HR+HER2− metastatic breast cancer post-CDK4/6 inhibitors, highlighting key biomarkers linked to response and resistance.

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies
Clinical Updatesantibody-drug conjugatesbreast cancer

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies

By MedXY|Sep 30, 2025

Antibody-drug conjugates (ADCs) have transformed breast cancer therapy but bring notable toxicity risks. This review examines the clinical evidence, adverse event management, and future directions for optimizing ADC use.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities